Literature DB >> 3134814

Risk factors and prognostic variables in the ovarian hyperstimulation syndrome.

D Navot1, A Relou, A Birkenfeld, R Rabinowitz, A Brzezinski, E J Margalioth.   

Abstract

This study was undertaken to clarify discriminative roles of multiple epidemiologic, hormonal, and biophysical variables for causation of ovarian hyperstimulation syndrome. Three hundred ninety-six patients with anovulatory infertility had ovulation induction with human menopausal gonadotropin throughout 1822 treatment cycles; 54 cycles (3%) were complicated by ovarian hyperstimulation syndrome. Early follicular serum estradiol and prolactin levels were higher in this group than in controls: 75.5 versus 46.2 pg/ml and 18.5 versus 11.7 ng/ml, respectively (p less than 0.01). On the day of human chorionic gonadotropin administration (day 0) the mean serum estradiol level was 1047 +/- 381 in the group with ovarian hyperstimulation syndrome and 719 +/- 339 pg/ml in controls (p less than 0.0001). In all follicular sizes and in all grades of ovarian hyperstimulation syndrome there was a tendency for more recruited follicles, with significantly more small follicles (12 to 14 mm) present on day 0 in all grades of ovarian hyperstimulation syndrome than in controls. Stepwise logistic regression performed on 22 variables identified a high-risk group for this syndrome; the major features are illustrated by young, lean patients who, after relatively few ampules of human menopausal gonadotropin, develop high estradiol levels and multiple small follicles.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134814     DOI: 10.1016/0002-9378(88)90523-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  24 in total

Review 1.  Ovarian hyperstimulation syndrome: a review of pathophysiology.

Authors:  P A Bergh; D Navot
Journal:  J Assist Reprod Genet       Date:  1992-10       Impact factor: 3.412

2.  [Combined GnRH agonist/hMG therapy and ovarian overstimulation syndrome].

Authors:  C Lindner; W Braendle; V Lichtenberg; G Bettendorf
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

3.  What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study.

Authors:  Theoni B Tarlatzi; Christos A Venetis; Fabienne Devreker; Yvon Englert; Anne Delbaere
Journal:  J Assist Reprod Genet       Date:  2017-07-14       Impact factor: 3.412

4.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

5.  Ovarian hyperstimulation: actual and theoretical risks.

Authors:  B H Smith; I D Cooke
Journal:  BMJ       Date:  1991-01-19

6.  Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes.

Authors:  David A Schirmer; Aniket D Kulkarni; Yujia Zhang; Jennifer F Kawwass; Sheree L Boulet; Dmitry M Kissin
Journal:  Fertil Steril       Date:  2020-07-14       Impact factor: 7.329

7.  Estradiol level on day 9 as a predictor of risk for ovarian hyperresponse during controlled ovarian hyperstimulation.

Authors:  Hsin-Yi Ho; Robert Kuo-Kuang Lee; Ming-Huei Lin; Yuh-Ming Hwu
Journal:  J Assist Reprod Genet       Date:  2003-06       Impact factor: 3.412

8.  Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review.

Authors:  Bernd Th Krause; Ralf Ohlinger; Annette Haase
Journal:  Biologics       Date:  2009-07-13

9.  Comparison of follicular fluid and serum levels of Inhibin A and Inhibin B with calculated indices used as predictive markers of Ovarian Hyperstimulation Syndrome in IVF patients.

Authors:  Jiri Moos; Karel Rezabek; Vanda Filova; Martina Moosova; Jana Pavelkova; Jana Peknicova
Journal:  Reprod Biol Endocrinol       Date:  2009-08-24       Impact factor: 5.211

10.  "hCG priming" effect in controlled ovarian stimulation through a long protocol.

Authors:  Panagiotis Beretsos; George A Partsinevelos; Eleni Arabatzi; Peter Drakakis; Depy Mavrogianni; Elli Anagnostou; Kostas Stefanidis; Aris Antsaklis; Dimitris Loutradis
Journal:  Reprod Biol Endocrinol       Date:  2009-08-31       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.